Core Viewpoint - The company has agreed to transfer 55% of its stake in Apollo back to Mingda Glasses, which will also repurchase the remaining shares, resulting in Apollo no longer being a non-wholly owned subsidiary of the company [1] Group 1: Transaction Details - The agreement involves the cancellation of bonds and the return of these bonds to the company for destruction, relieving the company of its obligations under the bond [1] - Following the completion of this transaction, the company will no longer hold any equity interest in Apollo [1] Group 2: Apollo's Business Overview - Apollo is an investment holding company registered under Hong Kong law, previously owned 55% by the company and 45% by Mingda Glasses [1] - Since 2002, Apollo has been engaged in lens distribution in mainland China, employing nearly 100 staff to distribute customized lens products to public hospitals, private hospitals, and ophthalmology centers [1] Group 3: Strategic Initiatives - The group has implemented several strategic initiatives, focusing on ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen [1] - The sale aligns with the company's strategy to optimize internal resource utilization [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 C-MER Medical Holdings Limited 希瑪醫療控股有限公司 （股份代號：3309） （於開曼群島註冊成立之有限公司） 須予披露交易及關連交易 涉及債券註銷的阿波羅股權出售事項 涉及債券註銷的阿波羅股權出售事項 於2025年12月17日，本 公 司 與 明 達 眼 鏡 訂 立 契 據，據 此(i)本公司已同意將待 售 股 份 轉 回 予 明 達 眼 鏡，而 明 達 眼 鏡 亦 已 同 意 向 本 公 司 回 購 待 售 股 份，相 當 於阿波羅全部已發行股本的55%；(ii)作 為 出 售 事 項 的 代 價，明 達 眼 鏡 已 同 意 將 債 券 註 銷 並 交 還 本 公 司 予 以 銷 毀，並 同 意 ...

Core Viewpoint - The company, Xiema Medical (03309), announced the cancellation of 23.218 million repurchased shares on December 11, 2025 [1] Summary by Category - **Company Actions** - Xiema Medical will cancel a total of 23.218 million shares that were previously repurchased [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年12月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) 03309 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事 ...

Core Viewpoint - Multiple companies conducted share buybacks on December 2, 2025, with Tencent Holdings leading in both volume and monetary value [1] Group 1: Buyback Details - Tencent Holdings (00700) repurchased 1.028 million shares for a total of 636 million [2] - Xiaomi Group-W (01810) repurchased 2.5 million shares for a total of 102 million [2] - COSCO Shipping Holdings (01919) repurchased 3 million shares for a total of 41.053 million [2] - China Feihe (06186) repurchased 4 million shares for a total of 16.74 million [2] - Gushengtang (02273) repurchased 378,400 shares for a total of 10.9452 million [2] Group 2: Cumulative Buyback Data - Tencent Holdings has a cumulative buyback of 82.018 million shares, representing 0.893% of its total share capital [2] - Xiaomi Group-W has a cumulative buyback of 78.2954 million shares, representing 0.300% of its total share capital [2] - COSCO Shipping Holdings has a cumulative buyback of 60.543 million shares, representing 2.102% of its total share capital [2] - China Feihe has a cumulative buyback of 195 million shares, representing 2.149% of its total share capital [2] - Gushengtang has a cumulative buyback of 10.4139 million shares, representing 4.395% of its total share capital [2] Group 3: Other Notable Buybacks - Other companies such as Kingsoft (03888), Fuhua Group (02038), and Weigao Group (01066) also participated in the buyback activities, with varying amounts and percentages of total shares repurchased [2][3] - The buyback activities reflect a trend among companies to return capital to shareholders amid market conditions [1]

Group 1 - The company, Hema Medical (03309), announced a share buyback plan on December 2, 2025, involving an expenditure of HKD 280,100 to repurchase 160,000 shares [1] - The repurchase price per share is set between HKD 1.75 and HKD 1.76 [1]

Core Viewpoint - The company, Hema Medical (03309.HK), announced a share buyback of 160,000 shares at a cost of HKD 280,000 on December 2nd [1] Group 1 - The total expenditure for the share buyback was HKD 280,000 [1] - The number of shares repurchased was 160,000 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年12月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存 ...

希玛医疗(03309)发布公告，于2025年12月1日，该公司斥资23.1万港元回购13.2万股股份，每股回购价 格为1.74-1.76港元。 ...

Core Viewpoint - On December 1, 2023, the company Xima Medical (03309.HK) announced a share buyback, spending HKD 231,000 to repurchase 132,000 shares at a price range of HKD 1.76 to 1.74 per share [1] Group 1 - The company executed a buyback of 132,000 shares [1] - The total expenditure for the buyback was HKD 231,000 [1] - The price per share for the buyback ranged from HKD 1.76 to 1.74 [1]